Key result
Screening campaigns for small molecules binding to the intracellular domains of human ERG or mouse EAG1 channels identified only compounds with weak, nonspecific binding.
Screening for non-pore-binding modulators of EAG K+ channels yielded only weak, nonspecific binders, indicating alternative strategies are required.
Answers are grounded in this paper and cite their sources.
Screening challenges intracellular EAG targeting; leaves open alternative strategies for selective K+ channel modulators.
Members of the ether-à-go-go (EAG) family of voltage-gated K(+) channels are involved in several pathophysiological diseases, and there has been a great interest in screening for drugs that modulate the activity of these channels. Many drugs have been shown to bind in the pore of these channels, blocking ion flux and causing disease pathology. In this report, we present two independent screening campaigns in which we wanted to identify small molecules that bind to either the intracellular cytoplasmic amino terminal Per-Arnt-Sim (PAS) domain from the human EAG-related gene (ERG) channel or the amino or carboxy terminal globular domains from the mouse EAG1 channel, affecting their interaction. We report that in both cases, compounds were identified that showed weak, nonspecific binding. We suggest alternative routes should be pursued in future efforts to identify specific, high-affinity binders to these cytoplasmic domains.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2016) studied this question. Small molecule screening was evaluated on Identification of specific, high-affinity binders to cytoplasmic domains. Screening campaigns for small molecules binding to the intracellular domains of human ERG or mouse EAG1 channels identified only compounds with weak, nonspecific binding.
Synapse has enriched 10 related papers. Consider them for comparative context: